The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10439 malaria professionals are enjoying the free benefits of MalariaWorld today

Treatment

Risk Factors for Malaria Infection and Seropositivity in the Elimination Area of Grand'Anse, Haiti: A Case-Control Study among Febrile Individuals Seeking Treatment at Public Health Facilities

May 29, 2020 - 14:24 -- Open Access
Author(s): 
Ashton RA, Joseph V, Eisele TP, et al.
Reference: 
Am J Trop Med Hyg. 2020 May 26.

The island of Hispaniola aims to eliminate malaria by 2025; however, there are limited data to describe epidemiologic risk factors for malaria in this setting. A prospective case–control study was conducted at four health facilities in southwest Haiti, aiming to describe factors influencing the risk of current and past malaria infection. Cases were defined as individuals attending facilities with current or recent fever and positive malaria rapid diagnostic test (RDT), whereas controls were those with current or recent fever and RDT negative.

Nanobiotechnological modules as molecular target tracker for the treatment and prevention of malaria: options and opportunity

May 19, 2020 - 14:12 -- Open Access
Author(s): 
Anamika J, Nikhar V, Laxmikant G, Priya S, Sonal V, Vyas SP
Reference: 
Drug Deliv Transl Res. 2020 May 7

Malaria is one of the major infectious diseases that remains a constant challenge to human being mainly due to the emergence of drug-resistant strains of parasite and also the availability of drugs, which are non-specific for their pharmacodynamic activity and known to be associated with multiple side effects. The disease has acquired endemic proportions in tropical countries where the hygienic conditions are not satisfactory while the environmental conditions favor the proliferation of parasite and its transmission, particularly through the female anopheles.

Cost-Effectiveness Analysis of Gender-Stratified Plasmodium vivax Treatment Strategies Using Available G6PD Diagnostics to Accelerate Access to Radical Cure

May 7, 2020 - 11:38 -- Open Access
Author(s): 
Devine A, Howes RE, Price DJ, Moore KA, Ley B, Simpson JA, Dittrich S, Price RN
Reference: 
Am J Trop Med Hyg. 2020 May 4

Tafenoquine has been licensed for the single-dose radical cure of Plasmodium vivax in adults; however, it is only recommended in patients with > 70% of normal glucose-6-phosphate dehydrogenase (G6PD) activity. Because this may hinder widespread use, we investigated gender-based treatment strategies in which all adult patients are tested with a qualitative G6PD rapid diagnostic test (RDT).

“We have this, with my husband, we live in harmony”: exploring the gendered decision-making matrix for malaria prevention and treatment in Nampula Province, Mozambique

March 31, 2020 - 15:59 -- Open Access
Author(s): 
Zoe Jane-Lara Hildon, Maria Escorcio-Ymayo, Rose Zulliger, Rosario Arias de Aramburú, Nan Lewicky, Hunter Harig, Jose Braz Chidassicua, Carol Underwood, Liliana Pinto and Maria Elena Figueroa
Reference: 
Malaria Journal 2020 19:133, 30 March 2020

Conceptualizing gender dynamics and ways of bridging entrenched gender roles will contribute to better health promotion, policy and planning. Such processes are explored in relation to malaria in Mozambique.

NOT Open Access | Gaps between Knowledge and Malaria Treatment Practices after Intensive Anti-Malaria Campaigns in Western Kenya: 2004-2016

March 23, 2020 - 14:08 -- NOT Open Access
Author(s): 
Zhou G, Hemming-Schroeder E, Gesuge M, Afrane YA, Lee MC, Atieli HE, Githeko AK, Yan G
Reference: 
Am J Trop Med Hyg. 2020 Mar 16

Effective case management is central for malaria control, but not all of those affected by malaria have access to prompt, effective treatment. In Kenya, free malaria treatment has been implemented since 2006. However, questions remain regarding effective treatment. We conducted cross-sectional epidemiological and questionnaire surveys in four counties in western Kenya in 2004, 2010, and 2016, and antimalarial availability surveys in 2016.

Evaluation of a capacity building intervention on malaria treatment for under-fives in rural health facilities in Niger State, Nigeria

March 2, 2020 - 14:52 -- Open Access
Author(s): 
Ayodele Jegede, Barbara Willey, Prudence Hamade, Fredrick Oshiname, Daniel Chandramohan, IkeOluwa Ajayi, Catherine Falade, Ebenezer Baba and Jayne Webster
Reference: 
Malaria Journal 2020 19:90, 24 February 2020

Despite the uptake of parasitological testing into policy and practice, appropriate prescription of anti-malarials and artemisinin-based combination therapy (ACT) in accordance with test results is variable. This study describes a National Malaria Control Programme-led capacity building intervention which was implemented in 10 States of Nigeria. Using the experience of Niger State, this study assessed the effect on malaria diagnosis and prescription practices among febrile under-fives in rural health facilities.

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

February 24, 2020 - 14:25 -- Open Access
Author(s): 
Gao J, Tian Z, Yang X
Reference: 
Biosci Trends. 2020 Feb 19

The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China.

NOT Open Access | Treatment of Severe Malaria in the United States

February 17, 2020 - 12:22 -- NOT Open Access
Author(s): 
John CC
Reference: 
Ann Intern Med. 2020 Feb 4;172(3):224-225

The American Society of Tropical Medicine and Hygiene (ASTMH) shares Krey and Travassos' (1) concerns about treatment of severe malaria in the United States.

Doses of chloroquine in the treatment of malaria by Plasmodium vivax in patients between 2 and 14 years of age from the Brazilian Amazon basin

December 30, 2019 - 14:46 -- Open Access
Author(s): 
Luann Wendel Pereira de Sena, Amanda Gabryelle Nunes Cardoso Mello, Michelle Valéria Dias Ferreira, Marcieni Andrade de Ataide, Rosa Maria Dias and José Luiz Fernandes Vieira
Reference: 
Malaria Journal 2019 18:439, 21 December 2019

A total dose of chloroquine of 25 mg/kg is recommended by the World Health Organization (WHO) to treat malaria by Plasmodium vivax. In several endemic areas, including the Brazilian Amazon basin, anti-malarial drugs are dispensed in small plastic bags at a dosing regimen based on age. This practice can lead to suboptimal dosing of the drug, which can impact treatment outcomes. The aim of the present study was to estimate the extent of sub-dosing of chloroquine in children and adolescents with vivax malaria using an age-based dose regimen, in addition to investigating the influence of age on the plasma concentrations of chloroquine and desethylchloroquine.

Monitoring of efficacy, tolerability and safety of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial

December 17, 2019 - 16:46 -- Open Access
Author(s): 
Bayode R. Adegbite, Jean R. Edoa, Ayola A. Adegnika, et al.
Reference: 
Malaria Journal 2019 18:424, 16 December 2019

Malaria remains a major public health problem, affecting mainly low-and middle-income countries. The management of this parasitic disease is challenged by ever increasing drug resistance. This study, investigated the therapeutic efficacy, tolerability and safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (AS–AQ), used as first-line drugs to treat uncomplicated malaria in Lambaréné, Gabon.

Pages

Subscribe to RSS - Treatment